Cardiac Science Announces Third Quart...(EVC Group Inc. Senior Vice President ...),Health

CSCX-F

                         - Tables to Follow -

    Cardiac Science Corporation and Subsidiaries
    Condensed Consolidated Statements of Operations (unaudited)
    (in thousands, except share and per share amounts)

                                              Three Months Ended
                                                 September 30,
                                           -----------------------
                                           2009               2008
                                           ----               ----
                                        $         %         $        %
                                       ---       ---       ---     ---

    Revenues:
      Cardiac monitoring products    $13,000    33.4%    $15,316   28.4%
      Defibrillation products         21,646    55.7%     34,071   63.1%
                                      ------    ----      ------   ----
          Total product
           revenues                   34,646    89.1%     49,387   91.4%
      Service                          4,238    10.9%      4,619    8.6%
                                       -----    ----       -----    ---
          Total revenues              38,884   100.0%     54,006  100.0%
                                      ------   -----      ------  -----

    Cost of Revenues:
      Products                        17,194    49.6%     24,799   50.2%
      AED field initiative            18,500    47.6%          -    0.0%
      Service                          3,095    73.0%      3,088   66.9%
                        
'/>"/>
SOURCE  Cardiac Science Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
Related medicine technology :

1. Personalized Medicine - The Genomic Revolution in Cardiac Care
2. FAU Receives Patent for Invention Which Induces and Restores Cardiac Muscle Function
3. Signalife Completes Testing of Modules for Holter and Intra-Cardiac Monitor
4. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
5. Study Shows Vernakalant Hydrochloride is Effective in Conversion to Normal Heart Rhythm in Atrial Fibrillation Patients Following Cardiac Surgery
6. FDA Concludes There is No Increased Risk of Cardiac Events for Patients Treated with omeprazole and NEXIUM(R) (esomeprazole magnesium)
7. Do-It-Yourself Cardiac Bypass Surgery: All You Need is Walking Shoes
8. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
9. Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death
10. DATATRAK and COResearch to Collaborate on Six Cardiac Safety Projects
11. Study Finds PCI Safe, Effective Despite Off-Site Cardiac Surgery